Literature DB >> 24648349

Differential effects of RUNX2 on the androgen receptor in prostate cancer: synergistic stimulation of a gene set exemplified by SNAI2 and subsequent invasiveness.

Gillian H Little1, Sanjeev K Baniwal2, Helty Adisetiyo2, Susan Groshen2, Nyam-Osor Chimge2, Sun Young Kim3, Omar Khalid3, Debra Hawes3, Jeremy O Jones3, Jacek Pinski2, Dustin E Schones3, Baruch Frenkel4.   

Abstract

Changes to androgen signaling during prostate carcinogenesis are associated with both inhibition of cellular differentiation and promotion of malignant phenotypes. The androgen receptor (AR)-binding transcription factor RUNX2 has been linked to prostate cancer progression but the underlying mechanisms have not been fully defined. In this study, we investigated the genome-wide influence of RUNX2 on androgen-induced gene expression and AR DNA binding in prostate cancer cells. RUNX2 inhibited the androgen response partly by promoting the dissociation of AR from its target genes such as the tumor suppressor NKX3-1. However, AR activity persists in the presence of RUNX2 at other AR target genes, some of which are cooperatively stimulated by androgen and RUNX2 signaling. These genes are associated with putative enhancers co-occupied by AR and RUNX2. One such gene, the invasion-promoting Snail family transcription factor SNAI2, was co-activated by AR and RUNX2. Indeed, these two transcription factors together, but neither alone stimulated prostate cancer cell invasiveness, which could be abolished by SNAI2 silencing. Furthermore, an immunohistochemical analysis of SNAI2 in archived primary prostate cancer specimens revealed a correlation with the RUNX2 histoscore, and simultaneous strong staining for SNAI2, RUNX2, and AR (but not any pair alone) was associated with disease recurrence. Overall, our findings suggest cooperation between AR and RUNX in the stimulation of oncogenes such as SNAI2, which might be targeted for individualized prostate cancer therapy. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24648349      PMCID: PMC4051204          DOI: 10.1158/0008-5472.CAN-13-2003

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  48 in total

1.  Opposing effects of Runx2 and estradiol on breast cancer cell proliferation: in vitro identification of reciprocally regulated gene signature related to clinical letrozole responsiveness.

Authors:  Nyam-Osor Chimge; Sanjeev K Baniwal; Jingqin Luo; Simon Coetzee; Omar Khalid; Benjamin P Berman; Debu Tripathy; Matthew J Ellis; Baruch Frenkel
Journal:  Clin Cancer Res       Date:  2011-12-06       Impact factor: 12.531

2.  Critical and reciprocal regulation of KLF4 and SLUG in transforming growth factor β-initiated prostate cancer epithelial-mesenchymal transition.

Authors:  Yen-Nien Liu; Wassim Abou-Kheir; Juan Juan Yin; Lei Fang; Paul Hynes; Orla Casey; Dong Hu; Yong Wan; Victoria Seng; Heather Sheppard-Tillman; Philip Martin; Kathleen Kelly
Journal:  Mol Cell Biol       Date:  2011-12-27       Impact factor: 4.272

Review 3.  Prostate derived ETS factor (PDEF): a putative tumor metastasis suppressor.

Authors:  Joshua J Steffan; Hari K Koul
Journal:  Cancer Lett       Date:  2011-06-29       Impact factor: 8.679

4.  Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer.

Authors:  Biswajyoti Sahu; Marko Laakso; Kristian Ovaska; Tuomas Mirtti; Johan Lundin; Antti Rannikko; Anna Sankila; Juha-Pekka Turunen; Mikael Lundin; Juho Konsti; Tiina Vesterinen; Stig Nordling; Olli Kallioniemi; Sampsa Hautaniemi; Olli A Jänne
Journal:  EMBO J       Date:  2011-09-13       Impact factor: 11.598

5.  Runx2 controls a feed-forward loop between androgen and prolactin-induced protein (PIP) in stimulating T47D cell proliferation.

Authors:  Sanjeev K Baniwal; Gillian H Little; Nyam-Osor Chimge; Baruch Frenkel
Journal:  J Cell Physiol       Date:  2012-05       Impact factor: 6.384

6.  Integration of regulatory networks by NKX3-1 promotes androgen-dependent prostate cancer survival.

Authors:  Peck Yean Tan; Cheng Wei Chang; Kern Rei Chng; K D Senali Abayratna Wansa; Wing-Kin Sung; Edwin Cheung
Journal:  Mol Cell Biol       Date:  2011-11-14       Impact factor: 4.272

7.  Runx2 in human breast carcinoma: its potential roles in cancer progression.

Authors:  Yoshiaki Onodera; Yasuhiro Miki; Takashi Suzuki; Kiyoshi Takagi; Jun-ichi Akahira; Takuya Sakyu; Mika Watanabe; Satoshi Inoue; Takanori Ishida; Noriaki Ohuchi; Hironobu Sasano
Journal:  Cancer Sci       Date:  2010-10-12       Impact factor: 6.716

8.  Runx2 transcriptome of prostate cancer cells: insights into invasiveness and bone metastasis.

Authors:  Sanjeev K Baniwal; Omar Khalid; Yankel Gabet; Ruchir R Shah; Daniel J Purcell; Deepak Mav; Alice E Kohn-Gabet; Yunfan Shi; Gerhard A Coetzee; Baruch Frenkel
Journal:  Mol Cancer       Date:  2010-09-23       Impact factor: 27.401

9.  The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis.

Authors:  Charles E Massie; Andy Lynch; Antonio Ramos-Montoya; Joan Boren; Rory Stark; Ladan Fazli; Anne Warren; Helen Scott; Basetti Madhu; Naomi Sharma; Helene Bon; Vinny Zecchini; Donna-Michelle Smith; Gina M Denicola; Nik Mathews; Michelle Osborne; James Hadfield; Stewart Macarthur; Boris Adryan; Scott K Lyons; Kevin M Brindle; John Griffiths; Martin E Gleave; Paul S Rennie; David E Neal; Ian G Mills
Journal:  EMBO J       Date:  2011-05-20       Impact factor: 11.598

10.  Regulation of breast cancer metastasis by Runx2 and estrogen signaling: the role of SNAI2.

Authors:  Nyam-Osor Chimge; Sanjeev K Baniwal; Gillian H Little; Yi-bu Chen; Michael Kahn; Debu Tripathy; Zea Borok; Baruch Frenkel
Journal:  Breast Cancer Res       Date:  2011-12-09       Impact factor: 6.466

View more
  17 in total

Review 1.  Glucocorticoid-Induced Osteoporosis.

Authors:  Baruch Frenkel; Wendy White; Jan Tuckermann
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622

2.  Estrogens and androgens inhibit association of RANKL with the pre-osteoblast membrane through post-translational mechanisms.

Authors:  Anthony Martin; Jiali Yu; Jian Xiong; Aysha B Khalid; Benita Katzenellenbogen; Sung Hoon Kim; John A Katzenellenbogen; Suchinda Malaivijitnond; Yankel Gabet; Susan A Krum; Baruch Frenkel
Journal:  J Cell Physiol       Date:  2017-05-11       Impact factor: 6.384

3.  Micro-RNA-204 Participates in TMPRSS2/ERG Regulation and Androgen Receptor Reprogramming in Prostate Cancer.

Authors:  Krassimira Todorova; Metodi V Metodiev; Gergana Metodieva; Milcho Mincheff; Nelson Fernández; Soren Hayrabedyan
Journal:  Horm Cancer       Date:  2017-01-03       Impact factor: 3.869

4.  Relationship between RUNX1 and AXIN1 in ER-negative versus ER-positive Breast Cancer.

Authors:  Nyam-Osor Chimge; Sara Ahmed-Alnassar; Baruch Frenkel
Journal:  Cell Cycle       Date:  2017-01-05       Impact factor: 4.534

5.  Estrogens and selective estrogen receptor modulators differentially antagonize Runx2 in ST2 mesenchymal progenitor cells.

Authors:  Yonatan Amzaleg; Jie Ji; Donlaporn Kittivanichkul; Anna E Törnqvist; Sara Windahl; Elias Sabag; Aysha B Khalid; Hal Sternberg; Michael West; John A Katzenellenbogen; Susan A Krum; Nyam-Osor Chimge; Dustin E Schones; Yankel Gabet; Claes Ohlsson; Baruch Frenkel
Journal:  J Steroid Biochem Mol Biol       Date:  2018-05-08       Impact factor: 4.292

6.  Glucocorticoids Hijack Runx2 to Stimulate Wif1 for Suppression of Osteoblast Growth and Differentiation.

Authors:  Eri Morimoto; Meng Li; Aysha B Khalid; Susan A Krum; Nyam-Osor Chimge; Baruch Frenkel
Journal:  J Cell Physiol       Date:  2016-04-26       Impact factor: 6.384

7.  Expression array analysis of the hepatocyte growth factor invasive program.

Authors:  Fabiola Cecchi; Chih-Jian Lih; Young H Lee; William Walsh; Daniel C Rabe; Paul M Williams; Donald P Bottaro
Journal:  Clin Exp Metastasis       Date:  2015-08-01       Impact factor: 5.150

8.  MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease.

Authors:  Raj R Bhanvadia; Calvin VanOpstall; Hannah Brechka; Nimrod S Barashi; Marc Gillard; Erin M McAuley; Juan Manuel Vasquez; Gladell Paner; Wen-Ching Chan; Jorge Andrade; Angelo M De Marzo; Misop Han; Russell Z Szmulewitz; Donald J Vander Griend
Journal:  Clin Cancer Res       Date:  2018-05-01       Impact factor: 12.531

Review 9.  Targeting transcription factors in cancer - from undruggable to reality.

Authors:  John H Bushweller
Journal:  Nat Rev Cancer       Date:  2019-09-11       Impact factor: 60.716

10.  Dynamic expression of SNAI2 in prostate cancer predicts tumor progression and drug sensitivity.

Authors:  Ying Z Mazzu; YuRou Liao; Subhiksha Nandakumar; Martin Sjöström; Lina E Jehane; Romina Ghale; Barani Govindarajan; Travis A Gerke; Gwo-Shu Mary Lee; Jian-Hua Luo; Sreenivasa R Chinni; Lorelei A Mucci; Felix Y Feng; Philip W Kantoff
Journal:  Mol Oncol       Date:  2022-02-11       Impact factor: 7.449

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.